by Portfolio Grader | February 26, 2014 10:30 am
This week, seven biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Pharmacyclics, Inc. (PCYC) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. In Portfolio Grader’s specific subcategories of Earnings Surprise and Sales Growth, PCYC also gets A’s. Shares of PCYC have increased 7.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
This week, Acorda Therapeutics, Inc.’s (ACOR) ratings are up from a C last week to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc.’s (NWBO) ratings are looking better this week, moving up to a B from last week’s C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
This week, Stemline Therapeutics, Inc. (STML) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Wall Street has pushed the stock higher by 7.3% over the past month. For more information, get Portfolio Grader’s complete analysis of STML stock.
Seattle Genetics, Inc. (SGEN) earns a B this week, jumping up from last week’s grade of C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Investors have pushed the stock price up 14.2% over the past month. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
This week, Amgen (AMGN) pushes up from a B to an A rating. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s price of $124.36 is nearing the 52-week high of $126.59. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
BioMarin Pharmaceutical (BMRN) shows solid improvement this week. The company’s rating rises from a C to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. Investors seem to agree with the upgraded status of the stock and have pushed the stock up 11.3% over the past month. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2014/02/7-biotechnology-stocks-to-buy-now-pcyc-acor-nwbo/
Short URL: http://invstplc.com/1ejMvnb